COLL

In a comparison of two medical-drugs stocks, Collegium Pharmaceutical (COLL) emerges as the better value investment option compared to Daiichi Sankyo (DSNKY). COLL holds a Zacks Rank of #1 (Strong Buy) with a Value grade of A, featuring a forward P/E of 3.14 and PEG ratio of 0.63. DSNKY has a Zacks Rank of #5 (Strong Sell) with a Value grade of C, showing a forward P/E of 18.47 and PEG ratio of 1.83.

Collegium Pharmaceutical (COLL) closed at $23.18 with a mean analyst price target of $49, suggesting 111.4% upside potential. The stock has a Zacks Rank #1 (Strong Buy) rating and shows positive earnings estimate revisions, with the consensus estimate for the current year increasing 3.8% over the last 30 days. However, the article cautions that price targets alone should not be the sole basis for investment decisions.

Zacks has added three stocks to its Strong Sell list today: Ardelyx (ARDX), a biopharmaceutical company with a 53.9% downward earnings revision; Southwest Airlines (LUV), a passenger airline with a 4.1% downward earnings revision; and Collegium Pharmaceutical (COLL), a specialty pharmaceutical company with a nearly 3% downward earnings revision over the last 60 days.

Collegium Pharmaceutical announced it will release third quarter 2026 financial results on November 5, 2026, before market open, followed by a live conference call and webcast at 8:00 a.m. ET. The biopharmaceutical company focuses on CNS and pain management treatments, with a portfolio including ADHD medications JORNAY PM and AZSTARYS.